Thermo Fisher Scientific Inc. has entered into a definitive agreement to acquire Brammer Bio, a viral vector manufacturer for gene and cell therapies, for approximately $1.7 billion in cash.   Brammer Bio works with biopharma customers to help deliver breakthrough medicines  leveraging the potential of gene therapies and gene-modified cell therapies. The company has nearly 600 employees at primary locations in Massachusetts and Florida. Brammer Bio anticipates $250 million of revenue in 2019. &...